other material
confidence high
sentiment neutral
materiality 0.55
Stockholders approve 2025 equity plan and executive option repricing to $1.50
Xilio Therapeutics, Inc.
- 2025 Stock Incentive Plan approved with 30.5M for, 2.9M against.
- CEO René Russo's 2,198,212 options repriced from $5.76 to $1.50.
- CFO Christopher Frankenfield's 848,172 options repriced from $4.67 to $1.50.
- CMO Katarina Luptakova's 225,210 options repriced from $4.10 to $1.50; effective after market close Nov 21.